Skip to main content
AstraZenecaAcquisition

AstraZeneca Acquires Omniose to Strengthen Vaccine Pipeline

Source: Autobound Signal API · 84 signals tracked for AstraZeneca · updated

Get AstraZeneca's live signals in Claude or ChatGPT, or by API

AskWhat changed at AstraZeneca this week? Use Autobound signals for astrazeneca.com.

What happened

AstraZeneca has acquired Omniose, folding the early-stage biotechnology firm into its infectious diseases division.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Nov 10 (Reuters) - AstraZeneca has acquired Omniose, an early-stage biotechnology firm developing vaccines against serious bacterial infections, and folded the business into its infectious diseases division, the target company said on Tuesday. ⢠"Omniose's bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections," said Benjamin Moutier, AstraZeneca's senior vice president of infectious disease ⢠Despite a diverse drug portfolio, AstraZeneca's on-market vaccine offerings are limited, and its CEO is refocusing on growth, with over 180 pipeline projects underpinning long-term ambitions ⢠AstraZeneca discontinued its Covid-19 vaccine in 2024, but now offers Beyfortus for respiratory syncytial virus infections and FluMist for influenza ⢠It is also exploring the development of cancer vaccines (Reporting by Raechel Thankam Job in Bengaluru; Editing by Vijay Kishore)

globalbankingandfinance.com/astrazeneca-bolsters-vaccine-pipeline-us-...Read the full source

Extracted by Autobound

From the Signal API record
Event
Acquisition

What this signalsIntegration work after a deal often opens needs for new systems and services.

Takes effect
Nov 10, 2026

Companies

  • OmnioseTargetomniose.com

More acquisition signals at other companies

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Nov 10, 2026
signal_type
news
signal_subtype
acquires

Use this data

Get every acquisition signal for AstraZeneca and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AstraZeneca this week?”

  2. Send it to your own tools

    The Signal API returns acquisition signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b5fe3bd3-f1e2-9b6b-ab61-925061f0c977 returns this record as JSON. POST /v1/companies/enrich returns every signal for astrazeneca.com.

{
  "signal_id": "b5fe3bd3-f1e2-9b6b-ab61-925061f0c977",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-11-10T14:29:40+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.globalbankingandfinance.com/astrazeneca-bolsters-vaccine-pipeline-us-biotech-omniose/",
    "title": "AstraZeneca Acquires Omniose to Strengthen Vaccine Pipeline - Global Banking & Finance Review",
    "excerpt": "Nov 10 (Reuters) - AstraZeneca has acquired Omniose, an early-stage biotechnology firm developing vaccines against serious bacterial infections, and folded the business into its infectious diseases division, the target company said on Tuesday. ⢠\"Omniose's bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections,\" said Benjamin Moutier, AstraZeneca's senior vice president of infectious disease ⢠Despite a diverse drug portfolio, AstraZeneca's on-market vaccine offerings are limited, and its CEO is refocusing on growth, with over 180 pipeline projects underpinning long-term ambitions ⢠AstraZeneca discontinued its Covid-19 vaccine in 2024, but now offers Beyfortus for respiratory syncytial virus infections and FluMist for influenza ⢠It is also exploring the development of cancer vaccines (Reporting by Raechel Thankam Job in Bengaluru; Editing by Vijay Kishore)",
    "summary": "AstraZeneca has acquired Omniose, folding the early-stage biotechnology firm into its infectious diseases division.",
    "planning": false,
    "image_url": "https://www.globalbankingandfinance.com/i/cloud-37a1bd5c-f0c1-45c3-aff7-e80579d49fdf/width=1200,height=630,quality=80,format=auto,fit=cover/",
    "confidence": 0.95,
    "published_at": "2026-11-10T14:29:40Z",
    "effective_date": "2026-11-10",
    "article_sentence": "AstraZeneca has acquired Omniose, an early-stage biotechnology firm developing vaccines against serious bacterial infections, and folded the business into its infectious diseases division, the target company said on Tuesday.",
    "related_company_name": "Omniose",
    "related_company_domain": "omniose.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.